Follow this preprint

GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of safety, pharmacokinetics, and potential therapeutic value

Erin Gaughan, Tariq Sethi, Tom Quinn, Nikhil Hirani, Andrew Mills, Annya M. Bruce, Alison MacKinnon, Vassilios Aslanis, Feng Li, Richard O’Connor, Richard A. Parker, John Norrie, James Dear, Ahsan R. Akram, Oliver Koch, Jie Wang-Jairaj, Robert J. Slack, Lise Gravelle, Bertil Lindmark, Kevin Dhaliwal
doi: https://doi.org/10.1101/2021.12.21.21267983
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Article Information

doi 
https://doi.org/10.1101/2021.12.21.21267983
History 
  • January 10, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Erin Gaughan1,2,
  2. Tariq Sethi3,*,
  3. Tom Quinn1,
  4. Nikhil Hirani1,2,
  5. Andrew Mills4,
  6. Annya M. Bruce1,
  7. Alison MacKinnon3,
  8. Vassilios Aslanis3,
  9. Feng Li1,
  10. Richard O’Connor1,
  11. Richard A. Parker5,
  12. John Norrie5,
  13. James Dear6,
  14. Ahsan R. Akram1,2,
  15. Oliver Koch7,
  16. Jie Wang-Jairaj3,
  17. Robert J. Slack3,
  18. Lise Gravelle3,
  19. Bertil Lindmark3 and
  20. Kevin Dhaliwal*,1,2
  1. 1Centre for Inflammation Research, Edinburgh BioQuarter, University of Edinburgh, Edinburgh, UK
  2. 2Department of Respiratory Medicine, New Royal Infirmary of Edinburgh, Edinburgh BioQuarter, Edinburgh, UK
  3. 3Galecto Inc. Ole Maaloes Vej 3, Copenhagen, Denmark
  4. 4Exploristics, Belfast, UK
  5. 5Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
  6. 6Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
  7. 7Infectious Diseases Department, NHS Lothian, Edinburgh, UK
  1. ↵*Corresponding authors Correspondence to: Tariq Sethi, TS{at}galecto.com, Evergreen House North, Grafton Place, Suite 908-910, London NW1 2DX; and Kevin Dhaliwal, Kev.Dhaliwal{at}ed.ac.uk, Centre for Inflammation Research, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh EH16 4TJ
Back to top
Posted January 10, 2022.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML

Supplementary Material

Data/Code
Email
GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of safety, pharmacokinetics, and potential therapeutic value
Erin Gaughan, Tariq Sethi, Tom Quinn, Nikhil Hirani, Andrew Mills, Annya M. Bruce, Alison MacKinnon, Vassilios Aslanis, Feng Li, Richard O’Connor, Richard A. Parker, John Norrie, James Dear, Ahsan R. Akram, Oliver Koch, Jie Wang-Jairaj, Robert J. Slack, Lise Gravelle, Bertil Lindmark, Kevin Dhaliwal
medRxiv 2021.12.21.21267983; doi: https://doi.org/10.1101/2021.12.21.21267983
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.